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Leukemia-derived human myeloid cell lines, such as the promyelocytic HL-60
(1) and ML3 (2), and the histiocytic U937 (3), are often used as models to study
terminal differentiation of myelomonocytic cells. DMSO (4), retinoic acid (RA)'
(5), and other substances induce HL-60 cells to differentiate along the myeloid
lineage, whereas 12-o-tetradecanoyl phorbol-13-acetate (TPA) (6), 1,25-dihy-
droxyvitamin Ds (7), and leukocyte products contained in medium conditioned
from PHA-activated leukocytes (PHA-CM) (8) induce myelomonocytic cells to
differentiate into cells with characteristics of monocyte/macrophages. PHA-CM
is also a potent inducer of differentiation of bone marrow myeloid cells (9) and
of leukemic cells from patients with chronic (CML) (9) or acute (AML) myeloge-
nous leukemia (9, 10). Cell lines and leukemic cells treated with PHA-CM stop
proliferating, undergo morphological changes, andacquire phenotypic and func-
tional characteristics ofdifferentiated cells (9, 11, 14). Partial monocytic differ-
entiation of human myeloid cell lines (9, 15-19) is induced by IFN-y, a potent
inducer of Fc receptors (FcR) for monomeric IgG (15), and of class II MHC
antigens (9). We have shown (9) that immune interferon (IFN-y) is as active as
PHA-CM to induce monocytic differentiation of CIVIL cells, and that treatment
of PHA-CM with antibodies to IFN-y abolishes almost completely its differentia-
tion-inducing activity. Also, PHA-CM in which IFN-y is neutralized with specific
antibodies or from which IFN-y has been removed by immune affinity chroma-
tography is less potent than untreated PHA-CM in inducing differentiation of
human myeloid cell lines (18). However, IFN-y is present in PHA-CM in
concentrations insufficient to account for its differentiation-inducing activity
(18), and other factors have been detected in IFN-y-depleted PHA-CM that
synergize with IFN-y to induce differentiation (18). Synergism between PHA-
CM and RA to induce differentiation ofHL-60 cells has also been demonstrated
(20).
With the exception of IFN-y, the differentiation-inducing factors in PHA-CM
This work was supported, in part, by U.S. Public Health Service Grants CA 10815, CA 20833, CA
32898, CA 37155, and CA 40256. M. Murphy is a predoctoral trainee supported by traning grant
CA 05022. B. Perussia is ascholar of the Leukemia Society of America.
' Abbreviations used in this paper:
￿
ANAE, a-naphthyl-acetate esterase; CM, conditioned medium;
CSF, colony-stimulating factor; FPLC, fast-protein liquid chromatography; G-CSF, granulocyte CSF;
LT, lymphotoxin; NBT, nitroblue tetrazolium; PdBU, phorbol-12,13-dibutyrate; PI, propidium
iodide; RA,retinoic acid; TNF, tumor necrosis factor; TPA, 12-o-tetradecanoyl phorbol-l3-acetate.
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are poorly characterized. Olsson et al. (21) reported that Con A-induced CM
obtained from human lymphocytes contained two distinct molecular species able
to induce differentiation: a species ofMr 25,000 that coelutes with the colony-
stimulating activity and a species of Mr 40,000 not associated with it. A differ-
entiation-inducing factor ofM, 36,000-58,000 was partially purified from PHA-
CM by Leung and Chiao (22), and a factor ofMr 46,000, acting on HL-60 cells,
and in synergy with RA, on U937 cells, was purified from supernatant of the T
lymphocyte line HUT-102 by Olsson et al. (23). In mice, granulocyte colony-
stimulating factor (G-CSF) induces differentiation of the myelomonocytic leu-
kemic line WEHI-3B (24). Human CSFO, a 30 kD molecule with properties
similar to mouse G-CSF, was recently purified from the CM of the human
bladder carcinoma cell line 5637 (5637-CM) and shown to induce differentiation
of both mouse WEHI-3B and human HL-60 cells (25).
Tumor necrosis factor (TNF) and lymphotoxin (LT) are two partially homol-
ogous factors originally described on the basis of their cytotoxic or cytostatic
effects on tumor cell lines: TNF as a tumor cytotoxic factor present in the serum
of animals injected with endotoxin (26), and LT as a class ofcytotoxic-cytostatic
substances released by lymphocytes upon antigenic or mitogenic stimulation (27,
28). The cytotoxic/cytostatic effects ofboth cytokines are potentiated by IFN-y
(29, 30). Recently (31-35), purification and cloning of the genes for TNF and
LT have allowed more detailed studies of the biology ofthese factors. The two
cytotoxins also appear to mediate regulatory effects on various cell types, e.g.,
they act as growth factors on fibroblasts (36, 37) and regulate proliferation,
differentiation, and functions of myelomonocytic cells at all stages ofdifferentia-
tion (38). In particular, we have demonstrated that a soluble factor that inhibits
myeloid and erythroid colony formation in vitro is produced by NK cells (39)
and has characteristics of TNF, and that LT and IFN-y, produced by mitogen-
activated T cells, act synergistically to block colony formation (40). Wee and
others (41) observed that TNF, LT, and INF-y act, alone or synergistically, to
activate human polymorphonuclear cell functions.
The presence of high concentrations of LT (40), and in some cases, of TNF
(our unpublished observation) in PHA-CM; the synergistic effect of TNF and
LT with IFN-y, reminiscent of that observed with the differentiation-inducing
factor in PHA-CM; and the original observation of Metcalf (42) that mouse
postendotoxin serum induces differentiation of WEHI-3B cells prompted us to
investigate the possibility that TNF and LT induce differentiation of myeloid
cells. In this paper we demonstrate that TNF and LT induce monocytic differ-
entiation ofhuman myeloid leukemic cell lines and that their effect ispotentiated
synergistically by IFN-y.
Materials and Methods
Cell Lines.
￿
All cell lines were grown in RPMI 1640 medium (Flow Laboratories, Inc.,
Rockville, MD). The human promyelocytic cell line HL-60 was maintained in medium
supplemented with 15% FCS (Gibco, Grand Island, NY); the human promyelocytic ML3,
2 B. Perussia, M. Kobayashi, M . E. Rossi, I. Anegon, and G. Trinchieri. Immune interferon
enhances functional properties of human granulocytes. Role of Fc receptors and effect of lympho-
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the histiocytic U937, the B lymphoblastoid RPMI 8866, the bladder carcinoma 5637, and
the mouse mastocytoma line P815y were maintained in medium supplemented with 10%
FCS. All cell lines used in this study were mycoplasma-free.
Monoclonal Antibodies.
￿
mAbs B9.8, B52.1, B33 .1, and B137.17 were produced and
characterized in our laboratory; OKMI, 5E9, 4F2, W6 .32, and BBM1 were produced
from cell lines obtained from the American Type Culture Collection (Rockville, MD);
3G8 was kindly donated by Dr. J. Unkeless (Mount Sinai Hospital, New York), and
KuFc79 was a gift of Dr. P. Gambel (Medical College of Virginia, Richmond, VA).
Antibodies B9.8 (IgM) (43) and OKMI (IgG2b; anti-C3bi receptor) (44) react with two
distinct antigens expressed on all differentiated neutrophilic granulocytes and monocytes,
and start to be expressed during differentiation, at the myelocytic and promyelocytic
stages, respectively. Antibody B52.1 (IgM) (14, 18) reacts with all peripheral blood
monocytes and all a-naphthyl acetate esterase (ANAE)-positive cells in the bone marrow,
and crosscompetes for binding to monocytes with antibody Mo2 (11, 45). Antibody B33.1
(IgG2a) (46) reacts with class II HLA antigens. Antibody 5E9 (IgGI) (47) reacts with the
transferrin receptor and antibody 4F2 (IgG2a) (48) with a dimeric structure (40 and 80
kD) present on monocytes, activated lymphocytes, and most proliferating cell types.
Antibody 3G8 (IgGI) (49) reacts with a surface molecule ofA 50,000-72,000, identified
as the low-affinity receptor for aggregated IgG on neutrophilic granulocytes, NK cells
and macrophages. The mouse monoclonal IgG2a B137.17 is an Ig of unknown specificity
selected on the basis of its high-affinity binding, in monomeric form, to the IFN-y-
inducible FcR on monocyte and myeloid cell lines.2 The binding of B137.17 to cells is Fc
fragment-dependent, and is blocked by monomeric human IgGI and IgG3 and murine
IgG2a and IgG3. Sepharose-linked B137.17 precipitates from human monocytes and
myeloid cell lines a molecule ofA 70,000, identified as the high-affinity FcR ofmonomeric
IgG. Antibody KuFc79 (IgG2b) (50) reacts with a 42 kD FcR species present on monocytes,
granulocytes, and B cells.
Conditioned Medium. Human peripheral blood mononuclear cells (separated on a
density gradient) were irradiated (20 Gy) and incubated (106 cells/ml) in RPMI 1640
medium supplemented with 1 % PHA-M (Wellcome Research Laboratories, Beckenham,
England) and 1% FBS for 72 h at 37 °C. Cell-free supernatant fluid was used as crude
PHA-CM preparation. Most preparations of PHA-CM contained 100-1,000 U/ml IFN-
y, and 10-40 U/ml LT. 5637-CM was obtained as cell-free supernatant fluid from 48-h
culture of the bladder carcinoma cell line 5637 in RPMI 1640 medium containing 0.2%
FBS. 5637-CM contained both pluripotent- and G-GSF activities (25, 51), but was devoid
of IFN-y, LT, or TNF activity.
LT and TNF Assays.
￿
Serial dilutions of samples were added to 3 X 10¢ mouse L-929
cells (a subline) per well in 96-well flat-bottomed microtiter plates in the presence of 1
,ug/ml actinomycin D (Calbiochem Behring Corp., La Jolla, CA). The concentrations
(U/ml) of cytotoxin for each sample were defined as the reciprocal of the dilution that
produced 50% cytopathic effect, as evaluated microscopically by cell rounding and
detachment.
Purification ofLTfrom RPMI 8866 Supernatant.
￿
RPMI 8866 cells (106 cells/ml) were
cultured at 37°C, 5% C02 for 48 h in serum-free RPMI 1640 containing 100 ng/ml of
phorbol-12,13-dibutyrate (PdBU) (Chemicals for Cancer Research, Inc., Eden Prairie,
MN) (52). The cell-free supernatants were harvested and concentrated 100-fold using a
Diaflow hollow-fiber cartridge (HIP 10-20 ; Amicon Co., Danvers, MA) and a stirred cell
(PM 10 membrane; Amicon Co.) . The protein concentrate was applied to a metal-chelating
Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden) column charged with CUS04 ,
5H20 (3 mg/ml) then equilibrated with 50 mM Tris-HCI buffer, pH 8 .0, containing 0.5
M NaCl. Unless otherwise cited, all the buffers used for purification contained 0.1 % PEG
8000 and 0.1 mM PMSF (Sigma Chemical Co., St. Louis, MO). After washing with the
same buffer, LT was eluted with 50 mM EDTA containing 1 .0 M NaCl and dialyzed
against 15 mM sodium phosphate buffer, pH 7.4, containing 135 mM NaCl (PBS). The
sample was then applied to a lentil lectin-Sepharose 4 B (Pharmacia Fine Chemicals)
column, eluted, and applied to a Mono Q (Pharmacia Fine Chemicals) column connectedTRINCHIERI ET AL.
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to a fast-protein liquid chromatography (FPLC) apparatus (Pharmacia Fine Chemicals).
LT was eluted with a linear (0-0 .25 M) NaCl gradient, and active fractions were
concentrated and loaded on an Ultragel AcA44 (LKB Produkter, AB, Bromma, Sweden)
column. After loading again on a lentil lectin-Sepharose 4 B column, and extensively
washing with PEG-free PBS, LT was eluted with 200 mM a-methylmannoside in PEG-
free PBS, and applied to a Pro RPC HR5/10 (Pharmacia Fine Chemicals) FPLC column.
Final elution of LT was with a linear (0-50%) ethylene glycol gradient in PBS.
For iodination, proteins were mixed for 20 min at 22 °C with 50 Al of 0.1 M Tris-HC1
buffer, pH 7 .4, and 0.5 mCi of carrier-free Na1211 in a polypropylene tube coated with 2
tag of 1,3,4,6-tetrachloro-3a-6a-diphenylglycouril. The reaction mixture was transferred
to another tube and mixed with 100 yl of NaI (2 mg/ml). Radiolabeled protein was
separated on a Sephadex G25 column and eluted with 0 .2% BSA in PBS. SDS-PAGE was
performed on 12 .5% polyacrylamide vertical slab gels. "C-labeled mol wt standards were
obtained from New England Nuclear (Boston, MA). After electrophoresis, gels were dried
and labeled protein bands were detected by autoradiography.
Cytokine Preparations.
￿
Purified human rIFN-7 from E. coli was kindly supplied by Dr.
H. M . Shepard (Genentech, Inc., South San Francisco, CA) and has an antiviral activity
titer of 7 X 107 U/mg on HeLa cells. Human rTNF (90% pure, 107 U/mg on L-929, a
subline, cells) was kindly supplied by Dr. J. S. Price (Cetus Corp., Emeryville, CA).
Induction ofMyeloid Cell Lines.
￿
HL-60 cells were seeded at 1 .5 X 105 cells/ml in RPMI
1640 supplemented with 15% FCS; ML3 and U937 were seeded at 105 and 0.75 X 105
cells/ml, respectively, in medium supplemented with 10% FCS. The various inducers of
differentiation were present throughout the culture period. Cultures were performed for
the indicated period in 24-well flat-bottomed plates or in plastic tissue culture flasks,
depending on the volume.
Cell Morphology and Cytochemistry.
￿
Cell morphology was examined on May-Grunwald-
Giemsa-stained cytocentrifuge preparations (Cytospin centrifuge; Shandon Southern
Instruments, Inc., Sewickley, PA). Staining for ANAE was according to Platt (53). Ability
of the cells to reduce nitroblue tetrazolium (NBT) (Sigma Chemical Co.) was determined
by mixing on a microscope slide 1 vol of cells in medium (5 X 106 cells/ml) and 1 vol of I
mg/ml NBT in NaCl, 0.15 M . After a 30-min incubation at 37° C in a humidified
atmosphere, slides were dried, stained with Wright-Giemsa, and the percentage of cells
containing blue-black formazan deposits was scored out of at least 200 cells.
Antibody-dependent Cell-mediated Cytotoxicity (ADCC).
￿
A 3-h "Cr-release assay was car-
ried out by incubating various numbers of effector cells in round-bottom microtiter plates
with 10' "Cr-labeled P815y cells sensitized with a 1 :200 dilution of a rabbit anti-P815y
antiserum. Supernatants were collected, and percent specific Cytotoxicity was calculated
as previously reported (54). Lytic units (LU) were calculated from Cytotoxicity curves
obtained at different E/T cell ratios using a modified van Krogh's equation as described
(54). One LU45 represents the number of effector cells required to mediate 45% specific
"Cr release from 10' target cells in the 3-h assay.
Indirect Immunofuorescence and Cell Cycle Analysis.
￿
Cells were sequentially incubated
with appropriate dilutions of the different mAbs (always in the presence of 5% human
serum, except for antibody B137 .17) and with FITC-labeled goat F(ab')2 anti-mouse Ig
for 30 min at 0 °C. The proportion of cells reactive with the different antibodies was
scored on a Cytofluorograf 50H (Ortho Diagnostics, Westwood, MA) connected to a Data
General MP/200 microprocessor. To determine the proportion of positive cells, the
threshold fluorescence intensity was used at which 99% of the cell population treated with
control supernatant from the parental myeloma cells and FITC-anti-mouse Ig antibodies
were negative. Mean fluorescence intensity is reported in arbitrary units, from I to 200,
and corresponds to the mean fluorescence channel of the positive cells. Fluorescence
intensity allows comparison of results only within each experiment; in order to allow
determinations on a sufficient number of cells, mean fluorescence intensity is reported
only when the percentage of positive cells is >5% .
For cell cycle analysis, cellspreviously stained or not with mAbs by indirect immunoflu-
orescence were fixed in ice-cold 70% ethanol for 10 min, spun, and resuspended at 22'C121 0
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in PBS containing RNase (62 jAg/ml) (Sigma Chemical Co.) and propidium iodide (PI)
(Sigma Chemical Co .) (0.2 jug/ml for stimultaneous analysis of antigenic phenotype and
cell cycle, 10 ug/ml for analysis of cell cycle only). Cells were analyzed with the Cytofluo-
rograf 50H, and the proportion of cells in Go/G1, S, and G2/M was determined using an
integration program on the MP/200 microprocessor.
[ H]TdR and ['H]Uridine Incorporation and Autoradiography.
￿
Cells were cultured in
96-well flat-bottomed microtiter plates (105 cells/ml, 200 Al/well) for the indicated periods
of time, and pulsed for the last 6 h of culture with 1 ACi/well of [5H]TdR or [6H]uridine
(New England Nuclear); cellswere collected on glass-fiber with an automated cell harvester
(Skatron, Sterling, VA), and the cell-associated radioactivity was assayed by liquid scintil-
lography. For autoradiography, cells were pulsed for 1 h with 5 ACi/ml of [6H]TdR,
smears were prepared on microscope slides, covered with NBT-2 emulsion (Eastman
Kodak Company, Rochester, NY), and developed after a 2-d exposure.
Chemiluminescence.
￿
HL-60 cells in Krebs buffer (106 cells/ml) were added (0.5 ml) to
scintillation vials, followed by addition of 0.5 ml of Krebs buffer containing 4 x 10-6 M
3-aminophthalhydrazide (Luminol; Sigma Chemical Co.), and dark-adapted for 1 h at
22 ° C. TPA (10-7M, Chemicals for Cancer Research Inc.) was then added, and chemilu-
minescence was measured at 22'C in a liquid scintillation counter in the out-of-coincidence
mode (55); cpm of each sample were recorded at 2-min intervals. Luminol alone gave a
background of 2 .5 ± 1 .4 x 10' cpm.
Phagocytosis-induced Protein Iodination.
￿
This assay was carried out according to the
method of Clarck and Szot (56) modified for microtiter plates. 50 JAI of cell suspension (5
x 106 cells/ml in Krebs buffer containing 400 nCi/ml 1251 (Amersham Corporation,
Arlington Heights, IL) were added, in triplicate, to 50 Eel of a suspension of serum-
activated zymosan (2 mg/ml) in Krebs buffer containing 50 mg/ml BSA (Sigma Chemical
Co.) as a source of protein . After 1-h incubation at 37 °C, the reaction was stopped by
adding 30 ul of a solution of 1 mM sodium metabisulfite and 10 mM KI, and proteins
were precipitated upon addition of 30 pl of 10% TCA. The suspension was layered on
silicone oil in microsediment tubes (Sarstedt, Princeton, NJ) and spun at 13,000 g for 2
min; the tips of the tubes containing the TCA-precipitable proteins were cut and pellet-
associated cpm were counted in a gamma counter. The number of '251 nmoles incorpo-
rated in the TCA-precipitable proteins was calculated from the amount of
1251 and from
the absolute number of cpm added per well. Background precipitable cpm in control
wells containing the reaction mixture but no cells were substracted, and were always
<0.1 % of input cpm.
Results
Purification of LT.
￿
LT was purified from serum-free conditioned medium of
PdBU-stimulated RPM18866 cells (52). LT produced by RPM18866 cells bound
tightly to metal-chelating Sepharose charged with Cue+ ions and to lentil lectin-
Sepharose. This protein had Mr of ^-40,000-60,000, by gel filtration. The final
preparation was purified ^-340-fold with a 3% recovery of activity and a sp act
of 6 .5 X 106 U/mg of protein. From 11 liters of cell supernatant, 2 ;Ig ofpurified
LT were obtained. SDS-PAGE of LT with or without DTT revealed a major
protein band of M, 20,000 consistent with the Mr of LT purified from RPM1
1788 as reported by Aggarwal et al. (31), and two minor protein bands of
undetermined origin at 60,000 and 18,000 M, positions (Fig. 1, lane 2). The LT
purified from RPMI 8866 cells also bound to mAb produced against RPM1 1788
LT (not shown) . The 20,000 M,. form of LT is probably a biologically active
degradation product of a native 25,000 form, as shown by Aggarwal et al . (32)
for RPMI 1788 LT.
Induction of Differentiation of HL-60 Cells by LT and TNF and Synergism with
IFN-y.
￿
A proportion of HL-60 cells cultured for 5 d in the presence of LT andTRINCHIERI ET AL .
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FIGURE 1 .
￿
Electrophoresis of purified LT and rTNF . LT, purified from supernatant of
RPMI 8866 cells, and rTNF were labeled with '25 1 and run on an SDS-12 .5% polyacrylamide
slab gel under reducing conditions. Bands were detected by autoradiography . Lane 1, mol wt
markers; lane 2, LT; lane 3, rTNF .
TNF expressed the monocyte-specific antigen recognized by antibody B52 .1, the
myelomonocytic antigen OKM 1 at higher density than untreated cells, ANAE
activity, and ability to reduce NBT (Fig . 2) . The expression of the myelomono-
cytic antigen recognized by antibody B9.8 was also increased (not shown),
whereas the proportion of cells bearing transferrin receptor, as detected with
antibody 5E9, was slightly decreased (Fig . 2D) . HL-60 cells cultured in the
presence of LT and TNF also mediated low levels of ADCC (Fig. 2A). rIFN-y
alone (100 U/ml) induced ADCC activity in HL-60 cells, but had only a minimal
effect on the expression of monocytic or myelomonocytic antigens and on ANAE
or NBT reduction activities (Fig . 2) . Addition of rIFN-y to LT and TNF
potentiated their ability to induce differentiation markers in HL-60 cells (Fig .
2) . The proportion of cells induced to express surface differentiation antigens
was additive when rIFN-y andLT orTNF were simultaneously present;however,
in the range of all concentrations tested, simultaneous addition of rIFN-y and
cytotoxins induced a higher proportion of cells than that induced by each
substance used separately . 4 U/ml of rIFN-y were sufficient to significantly
potentiate the ability of TNF to induce ADCC (Fig . 3A) or ANAE activity (Fig .
3B) in HL-60 cells, and the effects ofIFN-y andTNF were synergistic, as shown
in the isobologram analysis in the insets in Fig . 3 . A significant proportion of the
cells expressed differentiation markers after 24-h culture in the presence of
rIFN-y and TNF, and this proportion increased up to day 4-6, when maximal
differentiation was usually observed under the culture conditions used (not
shown) .
HL-60 cells treated with TNF and rIFN-y were smaller and more irregular
and vacuolated than control cells, and nucleoli and primary granules, present in
undifferentiated cells, were usually not detectable . A small proportion of the
cells became plastic-adherent and acquired macrophage-like morphology ; giant
multinucleated cells were often observed . Cell viability in the cultures was not1212
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￿
Induction of differentiation of HL-60 cells by rTNF, LT, and rIFN-y. HL-60
cells were incubated in the presence of the indicated concentrations of cytotoxins with or
without 100 U/ml rIFN-y, and assayed for: A, ADCC activity (E/T ratio, 50:1); B, reactivity
with antibody OKM1 ; C, reactivity with antibody B52.1 ; D, reactivity with antibody 5E9; E,
ANAE activity; F, ability to reduce NBT. Cells were cultured in medium containing: O, no
cytokine; N, 100 U/ml rIFN-y; O, rTNF; ", rTNF and 100 U/ml rIFN-y; A, LT; A, LT and
100 U/ml rIFN-y.
affected by the treatment and cell recovery from the cytokine-treated cultures
was 70-90% of that from the untreated control cultures.
Effect of TNF and IFN-y on Differentiation of HL-60, ML-3, and U937 Cell
Lines. The effect of5 U/ml rTNF, in combination or not with 100 U/ml rIFN-
y, in inducing various differentiation markers in two other human myeloid cell
lines was tested and compared with the effect of PHA-CM and 5637-CM, used
at 25% final concentration. PHA-CM contains IFN-y, LT, CSF activity, and
possibly other differentiation-inducing factors. 5637-CM lacks IFN-y, LT, and
TNF, and its ability to induce differentiation of cell lines has been attributed to
its CSF content. PHA-CM and 5637-CM induced ADCC activity in all three cell
lines. rTNF and rIFN-y, acting synergistically, induced higher levels of ADCC
activity in HL-60 cells than did PHA-CM or 5637-CM at the concentrations
used. rTNF and rIFN-y induced lower ADCC activity than PHA-CM in both
ML3 and U937 cells (not shown). Class II HLA antigens, detected by antibody
B33.1, were induced in ML3 cells only by rIFN-y and by IFN-y-containing PHA-
CM (Table I). rTNF (5 U/ml) and 5637-CM did not induce class 11 antigens;
however, rTNF potentiated the induction by rIFN-y. rTNF, used at 5 U/ml,
induced a significant proportion of HL-60, but not of the other cell lines, to
express the monocyte-specific antigen recognized by antibody B52.1 (Table 1).
rIFN-y (100 U/ml) was a poor inducer of this antigen, but it potentiated the120
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FIGURE 3.
￿
Synergism between rTNF and rIFN-y in inducing ADCC activity (A)and ANAE
activity (B) in HL-60 cells. HL-60 cells were cultured for 5 d in the presence of the indicated
concentrations of rTNF and: O, no rIFN-y; ", 4U/ml rIFN-y; A, 20 U/ml rIFN-y; or A, 100
U/ml rIFN-y. At the end of the incubation, the cells were washed and tested for ADCC
against antibody-sensitized P815y cells, and for ANAE. The insets in the figures are isobolo-
grams depicting synergism between rTNF and rIFN-y. The filled circles represent doses of
cytokines that induce 30 LU per 107 HL-60 cells (A) or that render 30% of HL-60 cells
positive for ANAE (B). The broken lines represent the hypothetical amounts of rTNF and
rIFN-y required to cause the same effectsassuming theinteraction was additive.
induction by rTNF. Expression of the receptor for C3bi, recognized by antibody
OKM1, was increased in all three cell lines upon incubation with any of the
inducers. Expression of OKM1 antigen was induced on HL-60 cells by rTNF
and rIFN-y more efficiently than by either PHA-CM or 5637-CM, which were
more effective inducers on U937 cells (Table I). Expression of OKM 1 antigen
was induced on ML3 cellsbya combinationofrTNF and rIFN-y moreeffectively
than by 5637-CM, but almost as effectively as by PHA-CM.
Proliferation and Cell Cycle Analysis ofDifferentiation Cells.
￿
^-1-2 U/ml rTNF
were sufficient to inhibit [sH]TdR incorporation by 50% on day 5, and rIFN-y
potentiated the inhibition in all three cell lines. [sH]TdR incorporation by HL-
60 cells was increased several-fold upon 24-h culture in the presence of rTNF,
either alone or with rIFN-y; this effect was not detectable on day 2, and inhibition
of [3H]TdR incorporation occurred at later times (Table II). By contrast, inhi-1214
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TABLE I
Effect of rTNF, rIFN-y and Other Differentiation Inducers on Surface Antigen Expression by Human
Myeloid Cell Lines
Cell lines were incubated for 5 d with the indicated inducers and assayed by indirect immunofluorescence for theexpression of the antigens
recognized by the three mAbs.
* Numbers in parentheses represent the average intensity of fluorescence on the positive cells (arbitrary units from 1 to 200).
TABLE II
Effect of rTNF on Proliferation, Thymidine Uptake and Uridine Uptake in HL-60 Cells
HL-60 cells were incubated for the indicated periods of time in culture medium with or without
20 U/ml rTNF.
* The proportion of cells in the S/G/M phases of the cell cycle was determined by flow-cytometry
analysis of cellsstained with PI.
Proportion of['H]TdR-incorporating cells wasevaluatedby autoradiographyaftera 1-hpulse with
['H]TdR (5 ACi/ml).
§ Incorporation of ['H]TdR and ['H]uridine was evaluated on cells cultured in flat-bottomed
microtiter plates (200 A]/well, initial concentration 2 x 104 cells/well).
bition of [3H]TdR incorporation by rTNF in ML3 and in U937 cells was
significant at 24 h, and became more dramatic at later times (not shown).
The effect of rTNF on proliferation of HL-60 cells was also analyzed by cell
cycleanalysis, autoradiography, and incorporation of[3H]uridine (Table II). The
number ofHL-60 cycling cells (S/G1/M phases) was slightly increased at 24 and
48 h, and decreased on days 3 and 4 ofculture. Analogous results were obtained
when the number of cells incorporating [3H]TdR was evaluated by autoradiog-
raphy: the number of positive cells was increased compared to control cells on
days 1 and 2, whereas a decrease ofalmost 50% was observed on days 3 and 4.
The results of [3H]uridine incorporation paralleled those of [3H]TdR, with
stimulation of incorporation at 24 h and a decrease on day 4.
The expression of differentiation markers on cells in different phases of the
cell cycle was analyzed by flow cytometry, with simultaneous analysis ofsurface
antigens (indirect immunofluorescence)andofcell cycle(PI staining). The results
Cellsin S/G2/M*
Cells
[
"incorporating ['II]TdR uptake¢ ['H]Uridine uptake¢
Day
No TNF 20 U/ml
rTNF No TNF 20 U/ml
rTNF No TNF 20 U/ml
rTNF No TNF
cpm
20 U/ml
rTNF
1 49 51 27 .0 33.0 2,614 7,658 4,658 6,831
2 56 63 33.5 49.5 6,782 7,054 6,804 6,134
3 56 44 41.0 34.5 ND ND ND ND
4 51 43 41 .1 21.5 18,258 6,126 18,247 5,929
Percentage cells positive
Inducer HL-60 ML3 U937
B33.1 B52.1 OKMI B33.1 B52.1 OKM1 B33.1 B52.1 OKM1
None 0.0 0.7 13.6(85)- 0.0 0.1 6.2(39) 1 .3 0.0 7.0(46)
riFN-y, 100 U/ml 0.0 1 .9 15.5 (94) 32.2 (52) 0.9 28.9 (42) 0.8 0.0 16.0 (58)
rTNF, 5 U/ml 0.0 8.4 (106) 29.9 (101) 1.5 0.6 28.9 (49) 0.2 0.0 11 .6 (46)
rlFN-y, 100 U/ml + 2.0 13.2 (130) 36.6 (101) 48.9 (64) 1 .9 57.6 (57) 0.8 0.2 32.2 (60)
rTNF, 5 U/ml
PHA-CM, 25% 0.0 12.4 (123) 28.9 (97) 10.3 (31) 2.9 70.6 (68) 1.0 1.8 65.7 (111)
5637-CM, 25% 0.0 12.0 (152) 24.2 (113) 1.2 2.1 20.7 (43) 1.2 2.0 45.8 (103)TRINCHIERI ET AL.
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Effect ofrTNF, LT, and rIFN-y on the luminol-enhanced chemiluminescence of
HL-60 cells. HL-60 cells were cultured for 5 d in the presence of the inducers, washed, and
tested forchemiluminescence in thepresence of 1.6 X 10' MTPA. HL-60cellswere cultured
in the presence of: O, culture medium; 0, 100 U/ml rIFN-y; A, 20 U/ml rTNF; A, 20 U/ml
rTNF and 100 U/ml rIFN-y; 0, 20 U/ml LT;0, 20 U/ml LT and 100 U/ml rIFN-y.
are illustrated in Fig. 4. Treatment of HL-60 cells with rTNF and rIFN-y
induced a decrease ofcycling cells (S/G2/M) from 40 to 25% on day 5 (Fig. 4A).
The monocyte-specific antigen recognized by antibody B52.1 (Fig. 4B) was
expressed on a small proportion of cells in G1 among the noninduced HL-60
cells, but was expressed at high density on a significant proportion of induced
cells in G, phase. The myelomonocytic antigen recognized by antibody OKM1
(C3bi receptor, Fig. 4C) was expressed in a proportion ofuninduced HL-60 cells
independent of the phase of the cell cycle, and after induction, became more
highly expressed, particularly on cells in the G, phase. The transferrin receptor
recognized by antibody 5E9 (Fig. 4D), and the antigen recognized by antibody
4172 (Fig. 4E) were expressedat high density on all uninduced HL-60 cells; after
culture with rTNF and rIFN-y, the intensity of expression of the two antigens
decreased on all cells, and a proportion ofcells in the G, phase did not express
the antigens, whereas all cycling cells remained positive.
Effect of TNF, LT, and IFN-y on Chemiluminescence and Phagocytosis by HL-60
Cells. HL-60 cells did not respond to TPA with luminol-enhanced chemilumi-
nescence (Fig. 5). After 5-d culture in the presence of rIFN-y, spontaneous and
TPA-induced chemiluminescence were increased by 3- and 20-fold, respectively.
HL-60 cells cultured in the presence of rTNF and LT alone had high levels of
spontaneous and TPA-induced chemiluminescence, which were enhanced when
rIFN-y was present during the culture with either cytokine. HL-60 cells cultured
for 5 d with 20 U/ml rTNF and 100 U/ml rIFN-y showed a 30- and 100-fold
increase in spontaneous and TPA-induced chemiluminescence, respectively.
The ability of HL-60 cells to ingest C3-activated zymosan particles was tested
using the method ofphagocytosis-induced protein iodination (Table III), which
evaluates the function of the myeloperoxidase-H202-halide system in phagocy-
tosing cells. Both rTNF and rIFN-y increased the phagocytic ability of HL-60TRINCHIERI ET AL.
TABLE III
rTNF and rIFN-y Induce HL-60 Cells to Mediate Iodination of
Proteins upon Phagocytosis ofSerum-activated Zymosan
TABLE IV
HL-60 cells were cultured for 5 d in the presence of rIFN-y and rTNF
at the indicatedconcentrations, and assayed for ability to iodinate BSA
when stimulated to phagocytize by serum-activated zymosan.
* TCA-precipitable 251 oxidized by 2.5 x 105 HL-60 cells during 1-h
incubation.
Expression of FcR on HL-60 Cells Treated with rTNF and rIFN-y
HL-60 cells were cultured for 5 d in the presence of rTNF (20 U/ml),
rIFN-y (100 U/ml), or a combination of the factors. Percent positive
cellsas detected by indirect immunofluorescence (flowcytometry). The
threshold fluorescence intensity at which 99% of the cells without first
antibody added were negative was determined on HL-60 cells cultured
in the absenceof differentiation inducers and used for all the samples.
* Numbers in parentheses indicate the average intensity of fluorescence
(on an arbitrary scalefrom 1 to 200) of the positive cells.
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cells in a dose-dependent manner. The amount of '251 oxidized per cell by HL-
60 cells induced by a combination ofthe two cytotokines was approximately half
of that oxidized by fresh peripheral blood polymorphonuclear cells (5.3 ± 0.6
nmoles per 2.5 X 105 cells/h).
Expression of Different FcR Types on HL-60 Cells Induced with rTNF and
rIFN--y. The results of the analysis of FcR expression on HL-60 cells during
differentiation are shown in Table IV. The low-affinity FcR ofneutrophils, NK
cells, and macrophagesrecognized byantibody 3G8 was poorly inducedby rTNF
or rIFN--y. The expression of the 42 kD FcR of neutrophils, monocytes, and B
cells recognized by antibody KuFc79 was not significantly affected by rTNF and
rIFN--y. Expression of the high-affinity FcR for monomeric IgG, detected by
binding of monoclonal IgG2a B137.17, was strongly enhanced by rIFN-^y but
not by rTNF. However, rTNF potentiated the effect of rIFN-y in inducing the
receptor.
mAb
Percentage of cells
treatment
staining positively
with:
with mAbs
None rTNF rIFN-y rTNF + rIFN-y
None 1.0 2.0 2.1 3.2
3G8 10.7 (72)* 18.5 (75) 18.7 (87) 25 .1 (84)
KuFc79 83 .2 (43) 78.2 (44) 72.4 (45) 77.7 (51)
B137 .17 83 .9 (53) 71 .2 (44) 93.4 (104) 94 .5 (133)
rIFN-y
"5I oxidized*
0
by HL-60cells
1
given rTNF
10
(U/ml)
100
nmol
0 0.32 0.78 1.30 1.60
20 1.64 2.19 2.51 2.33
100 2.41 2.94 2.99 2.47121 8
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Discussion
In this paper we demonstrate that TNF and LT, two cytotoxins produced by
different cell types, are potent inducers of myeloid cell differentiation along the
monocytic lineage. HL-60, and to a lesser extent, ML3 and U937 cells, cultured
for a few days in the presence of rTNF or LT at concentrations of ^, 10-" M,
coordinately express a series of differentiation markers, surface antigens, enzy-
matic activities, and cellular functions typical of monocyte/macrophages, while
concomitantly showing a reduced proliferative ability. Most cells are induced to
expressthe variousdifferentiation markersat high density, and formost markers,
the induction is synergistically potentiated by IFN-y. This terminal differentia-
tion of leukemic cell lines, induced by the synergistic effect of cytotoxins and
IFN-y, closely resembles that induced by lymphokines contained in PHA-CM (8,
14, 18). PHA-CM contains both LT and IFN-y, and we have shown that
synergism between the two lymphokines is required to inhibit proliferation of
normal myeloid precursor cells by PHA-CM (40). LT and IFN-y are both
produced by T cells, and we proposed that secretion of the two lymphokines is
responsible for hematopoietic colony inhibition in vitro by activated T cells, and
possibly for bone marrow failure in some pathological conditions (40). Experi-
ments in progress using a sensitive and specific RIA have detected low concen-
trationsofTNF in some, but not all, PHA-CM. We havealso observed that PHA
and other cell mitogens induce production of TNF by peripheral blood mono-
nuclear cells at early times of culture. Therefore, PHA-CM could contain
different factors able to affect cellular differentiation, depending on the culture
conditions and on the time ofits harvest used in the different studies; this might
explain some of the minor discrepancies of the results obtained in different
laboratories (18, 21-23).
HL-60 cells, cultured in the presence of TNF or LT alone, are efficiently
induced to express some differentiation markers, e.g., myelomonocytic and
monocytic antigens. Although IFN-y alone is not veryeffective in inducing these
surface markers, it potentiates the effect of cytotoxins, although a clear synergis-
tic effect is not observed. Both cytotoxins and IFN-y induce ADCC activity,
ANAE, NBT reduction ability, phagocytosis, and chemiluminescence in HL-60
cells, and the two classes of factors synergize to induce these cellular markers
and functions. Cytotoxins alone, at the doses used in this study, do not induce
expression of high-affinity FcR or class II MCH antigens on myeloid cells,
whereas IFN-y is very efficient in inducing both types of surface molecules;
TNF, however, potentiates this effect of IFN-y.
We have previously (18) shown that the differentiation-inducing ability of
PHA-CM on HL-60 and ML3 cells is due to the synergistic effect of IFN-y and
one or more undefined differentiation-inducing activities. The effect of IFN-y-
depleted PHA-CM is very similar to that of TNF and LT, i.e., significant
induction of surface myelomonocytic antigens, modest or no effect on ADCC
and ANAE, and no effect on FcR and class II antigen expression (18). The
synergistic effect of IFN-y-depleted PHA-CM and rIFN-y precisely mimics that
between cytotoxins and rIFN-y described in the present study. The concentra-
tions of both LT and IFN-y in PHA-CM are sufficient to account for the
differentiation-inducing effect of PHA-CM on HL-60 cells. However, differen-TRINCHIERI ET AL.
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tiation factors other than LT and IFN are probably present in the PHA-CM, as
suggested by (a) studies showing heterogeneity ofdifferentiation-inducing factors
in PHA-CM (21), (b) the inability of anti-LT antibodies to completely suppress
the differentiation-inducing abilityofunfractionated PHA-CM (our unpublished
results), and (c) the present observation that cytotoxins and IFN-'r are efficient
inducers ofdifferentiation ofHL-60 and ML3, but less so ofU937 cells, whereas
PHA-CM effectively induces all three cell lines. 5637-CM, which contains CSF-
0 but neither cytotoxins nor IFN-y, is also a potent inducer ofdifferentiation of
the three cell lines (25, 57). IFN-y only modestly potentiated the differentiation
induced by 5637-CM (our unpublished observation). Whether CSF-,B or other
CSF types play a role in the induction ofdifferentiation ofcell lines by PHA-CM
is still undetermined.
HL-60 cells stimulated with TPA, Ca" ionophore, and bacterial LPS produce
high levels ofTNF (35) with 10-20 min ofstimulation, suggesting the possibility
that HL-60 cells constitutively produce TNF and that differentiation in these
cells upon exposure to IFN-y occurs in response to autocrine stimulation.
However, using RIA sensitive to TNF concentrations lower than 10-'2 M, we
could not detect any TNF produced by HL-60 cells, either constitutively or upon
stimulation with IFN--y. IFN-y has been shown (58) to induce TNF production
by normal peripheral blood mononuclear cells and by fresh bone marrowsamples
containing these cells. This observation could perhaps explain why IFN'y, a
modest inducer ofdifferentiation of myeloid cell lines (18), is as potent as PHA-
CM in inducing monocytic differentiation in fresh preparations ofbone marrow
cells from both healthy donors or CML patients (9).
The synergism between IFN-y and cytotoxins is similar to that previously
observed for the cytotoxic/cytostatic effects of the cytotoxins (29, 30, 39, 40).
IFN--y induces a twofold increase of surface expression of the TNF receptors in
most cell lines (59-61). Such an increase probably accounts, in part, for the
synergistic effect between TNF and IFN-y, but other mechanisms are likely to
play a role, as shown by significant synergistic effects on cell lines in which
increased expression of TNF receptors is not detected (61). The differential
efficiency of IFN-y in synergizing for the various effects of TNF on HL-60 cells
suggests that the synergy between IFN-y and TNF cannot be explained solely
on the basis of an increased TNF receptor expression. The unique ability of
IFN-y to increase the expression of high-affinity FcR on myeloid cells (15) can
in part explain the synergism with TNF in inducing ADCC activity in these cells,
but this effect does not account for the strong synergism in the induction ofFcR-
independent markers such as ANAE, chemiluminescence, or NBT reduction. Of
the three types of FcR analyzed in this study, the expression of the high-affinity
FcR for monomeric IgG is strongly enhanced on HL-60 cells induced to differ-
entiate by rIFN-y and rTNF, whereas only aminor proportion ofcells is induced
to express the low-affinity receptor recognized by antibody 3G8 (49). The
expression of a third type of FcR, recognized by antibody KuFc79 (50), is not
changed during differentiation of HL-60 cells. Although partial correlation is
observed between the expression of high-affinity FcR and ADCC mediated by
the three cell lines, the exact role played by the three types ofFcR in endowing
the cells with ADCC activity remains to be determined.1220
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As in HL-60 cells induced to differentiate by PHA-CM (14, 62), the prolifer-
ative capacity of myeloid cell lines in the presence of TNF for several days was
inhibited, as indicated by a decrease in [3H]TdR incorporation and in the number
of cells in the S/G2/M phases of the cell cycle. The monocytic surface antigen
recognized by antibody B52.1, expressed in a very small proportion of HL-60
cells in G, phase, was expressed in a much larger proportion of G, cells after
induction with TNF and IFN-y. These results could be interpreted on the basis
ofa cell cycle-dependent expression of B52.1 antigens. However, we previously
(14) observed that, upon induction with PHA-CM, a subset of HL-60 cells stops
proliferating and coordinately expresses B52.1 antigen, ANAE activity, C3b
receptor, and ability to mediate ADCC. It is more likely that the differentiated
cells accumulate in G, and express B52.1 antigen; the small proportion ofB52.1+
cells in G, phase in control HL-60 cultures probably represents the small number
of cells spontaneously differentiating along the monocytic pathway.
Expression of the transferrin receptor was previously shown (63) to decrease
on HL-60 cells induced to differentiate, correlating with the decreased prolifer-
ation in the culture. In this paper, we show that the expression of transferrin
receptor and of the proliferation-associated antigen recognized by antibody 41`2
decreases on HL-60 cells induced to differentiate by TNF and IFN-y. A popu-
lation of cells in G, phase, which do not express transferrin receptor or 4F2
antigen, can be identified in induced HL-60 cells, whereas all cells still prolifer-
ating in the presence ofTNF and IFN-y express the two antigens.
When [3H]TdR incorporation and cell cycle analysis were performed on HL-
60 cells at early times ofculture, a stimulatory effect ofTNF was observed . This
effect was observed using both high TNF concentrations and doses lower than
those inducing differentiation. Anti-TNF antibodies blocked the stimulation
effect (not shown), indicating that this was not due to contaminants present in
the TNF preparations. These results, showing increased [3H]TdR incorporation
by TNF-treated cells, constitute further evidence that the observed effects of
TNF on differentiation of HL-60 cells are not secondary to a generalized toxic
effect of the cytotoxin. The results obtained with TNF on HL-60 cells closely
resemble those reported by Elias et al. (64), who demonstrated a very similar
effect of PHA-CM on HL-60 but not on U937 cells. The strong increase in
[3H]TdR and [3H]uridine incorporation was paralleled by a modest increase, at
24 and 48 h, in the proportion of cycling cells (PI analysis) and of cells incorpo-
rating [3H]TdR (as analyzed by autoradiography). Thus, as demonstrated by
Elias et al. (64) with PHA-CM, the effect ofTNF on [3H]TdR uptake might rest,
in large part, on an increased TdR accumulation in the intracellular nucleotide
triphosphate pool, and also in an expanded population of cells in active DNA
synthesis.
Increased production of cytotoxins and IFN-y is observed in vivo in various
pathological situations such as infections, tumor growth, autoimmune diseases,
and during immune response. Indeed, these cytokines act directly on the prolif-
erative ability of infectious agents or tumor cells, and indirectly, on the cellular
types involved in both adaptive and natural immune resistance to these patho-
gens. Wee (38-40, 65) and others (41) have shown that cytotoxins and IFN
mediate complex effects on cellular proliferation, differentiation, and functionalTRINCHIERI ET AL.
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activities of myelomonocytic cells at all stages of maturation, from the committed
precursor cells to the terminally differentiated polymorphonuclear cells and
macrophages. Other cytotoxin-induced effects are targeted on cell types such as
fibroblasts, adipocytes and hematopoietic cells (36, 37, 66). Thus, these soluble
mediators might be active at low concentrations in physiological conditions and
represent a hormone-like class of substances, that, through suppressive and
stimulating synergistic and antagonistic effects, contribute to the homeostasis of
the whole organism, and in particular, the hematopoietic system.
Summary
We show that the cytotoxins tumor necrosis factor (TNF) or lymphotoxin
(LT), at concentrations of ^-10-' 1 M induce monocytic differentiation of human
myeloid cell lines. After 5 d of culture in the presence of rTNF and LT, a
significant proportion of the myeloid cell lines express monocyte differentiation
antigens and ANAE activity, and become able to reduce nitroblue tetrazolium
(NBT) and mediate low levels ofADCC against tumor target cells. These markers
of differentiation, however, are maximally induced when rIFN-y, at concentra-
tions as low as 4 U/ml, is present simultaneously with the cytotoxins, and the
two classes of cytokines act synergistically to induce terminal differentiation. The
appearance of monocytic antigens is accompanied by acquisition of morphology
and other functional properties of mature monocytic cells, such as chemilumi-
nescence and phagocytosis, and by expression of FcR for monomeric IgG. A
decrease in cell proliferation accompanies induced differentiation, and is not due
to the cytotoxic properties of TNF or LT, as indicated in simultaneous analysis
of surface phenotype and cell cycle. The lack of cytotoxicity of TNF on the HL-
60 cell line is also demonstrated by the enhancing effect of TNF on HL-60 cell
growth and nucleoside uptake in the first 2 d of culture. These data show that
the cytotoxins TNF and LT mediate complex effects on cells of the myelomon-
ocytic lineage and, in synergy with IFN--y, can fully induce immature myeloid
cells to differentiate into cells with phenotypic, functional, and proliferative
characteristics of terminally differentiated myelomonocytic cells.
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